Biologic drugs, developed from living cells and organisms, can stimulate the human body to combat debilitating diseases such as cancer, rheumatoid arthritis, and multiple sclerosis. While biologics are a major achievement in medicine, the cost of procuring these drugs continues to pose challenges to the health care system. The development and sale of biosimilars—drugs that are designed to share the structure and functionality of innovator biologics—offer a promising option to promote affordability in the biologics market through competition. During this briefing, panelists explained the mechanisms of biologic drugs, explore the impact of current regulations on the uptake of biosimilars, and discussed considerations for the biosimilars market in the United States.
- Sameer V. Awsare, M.D., FACP, associate executive director, The Permanente Medical Group, Kaiser Permanente
- Adam J. Fein, Ph.D., chief executive officer, Drug Channels Institute
- Anna Hyde, M.A., vice president, advocacy and access, Arthritis Foundation
- Jeremy Sharp, senior vice president, Waxman Strategies